- TherageniX receives £995,000 grant from Innovate UK to develop their groundbreaking powdered gene therapy technology for bone regeneration.
- Collaboration with the University of Nottingham offers a non-viral gene delivery system, aiming to significantly improve patient outcomes following orthopedic surgery.
- The cutting-edge technology holds the potential to revolutionize tissue repair strategies, creating new standards in the healthcare sector.
A Game-Changing Grant to Fuel Medical Revolution
In a marriage of academia and entrepreneurial spirit, TherageniX, a University of Nottingham spin-out, recently secured a £995,000 grant from Innovate UK to pioneer a dry powder gene therapy formulation aimed at augmenting bone graft procedures. This funding, part of Innovate UK’s Transforming Medicines Manufacturing programme, comes as a boost to the innovative startup focused on tissue regeneration.
Rapid Transformation of Gene Delivery
This is not merely a technological advancement; it’s a paradigm shift. Traditionally, gene therapy has been constrained by the limitations of viral delivery mechanisms, which come with their own set of challenges and risks. TherageniX’s proprietary technology allows for the rapid transfection of patient cells with the gene(s) of interest. This intra-operative procedure is followed by implanting the altered cells back into the surgical site, enabling the body to produce the necessary proteins or factors for tissue repair. With this grant, the startup is keen to fine-tune its non-viral gene delivery system by transitioning from liquid to dry powder formulation.
Why Focus on Orthopedics First?
Orthopedic surgeries often necessitate bone grafting—a complex and sensitive process. Currently, transplantation of autologous bone is the go-to strategy. But it’s far from perfect. Bone implants can fail for various reasons: poor integration, infection at the harvest site, or simply unsatisfactory functionality. These drawbacks can result in delayed recovery, potential re-operation, diminished quality of life, and soaring medical costs.
In steps TherageniX, which aims to improve the regenerative capacity of skin, bone, muscle, and cartilage following surgery. Their technology combines autologous bone marrow cells from patients with a platform that produces genes crucial for tissue regeneration, like BMP for osteogenesis.
Efficiency, Efficacy, and Economics
One of the selling points of TherageniX’s technology is that it smoothly integrates with established surgical procedures. The process of rapid cell transfection adds no extra time in the operating theater, thus improving overall surgical efficiency. The grant will not only accelerate the company’s R&D pipeline but also enable them to refine the cost-effectiveness of the technology—important factors for both healthcare providers and payors.
A Visionary Collaboration with the University of Nottingham
Dr. Anandkumar Nandakumar, CEO of TherageniX, said, “This grant is testament to the potential of TherageniX’s novel approach to tissue regeneration.” This mirrors the vision of Dr. James Dixon, Associate Professor of the School of Pharmacy and NIHR Nottingham Biomedical Research Centre at the University of Nottingham, who has been nurturing this gene delivery platform for several years. The union between academic research and commercial applicability is poised to create transformative solutions for poorly addressed clinical problems.
Beyond Orthopedics: The Wider Implications
Although the initial focus is on orthopedic applications, the technology holds broader possibilities. Its adaptability makes it a viable solution for various other tissues and surgical procedures. The team at TherageniX has their sights set on a future where their system can be employed in emergency medicine, thus widening the scope of regenerative medicine and gene therapy applications.
Securing the Future
TherageniX was incorporated in 2022 with the backing of Nottingham Technology Ventures Ltd and built by NLC, the European healthtech venture builder. With nearly a million pounds of funding now in their coffers, they are better poised to engage with prestigious funding bodies and investors to take their ground-breaking solution from the lab to the operating room and, eventually, to the global market.
Gene therapy has long been the future of medicine. But thanks to the efforts of startups like TherageniX, in collaboration with academic bodies like the University of Nottingham, and with significant support from Innovate UK, that future is increasingly becoming the present. Their cutting-edge gene therapy technology promises to make waves not just in bone regeneration but also in the broader landscape of regenerative medicine.
For more information about TherageniX’s proprietary gene therapy technology or investment opportunities, visit www.theragenix.health.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!